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Abstract Colorectal cancer is one of the most common
tumors worldwide and at least 50 % of patients with this
disease develop metastases. In this setting, additional
treatment options are needed for patients presenting disease
progression after exhausting all standard therapies. Rego-
rafenib is an orally administered multikinase inhibitor
which has been shown to provide survival benefits to
patients with metastatic colorectal cancer (mCRC).
Although most adverse events (AEs) associated with
regorafenib may resolve within the first 8 weeks of treat-
ment, some of them may require dose reduction or treat-
ment interruption. Overall, while remaining aware of the
safety profile of regorafenib and how to manage the most
common toxicities related to its use, this drug should be
considered a new standard of care for patients with pre-
treated mCRC. This review addresses practical aspects of
its use, such as dosing, patient monitoring, and manage-
ment of the most common regorafenib-related AEs.
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Introduction
Colorectal cancer is one of the most common tumors
worldwide and over 50 % of patients with this type of
tumor develop metastases. Standard treatment for meta-
static colorectal cancer (mCRC) includes chemotherapy
based on fluoropyrimidines, oxaliplatin and irinotecan, as
well as monoclonal antibodies such as bevacizumab, ce-
tuximab and panitumumab [1, 2] and human recombinant
fusion proteins, such as aflibercept [3]. Nonetheless, addi-
tional options are needed for patients presenting disease
progression after exhausting all standard therapies. Rego-
rafenib is an orally administered multikinase inhibitor [4].
This agent targets cell-signaling pathways involved in
oncogenesis and progression, including protein kinases
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associated with angiogenesis, such as vascular endothelial
growth factor receptors 1–3 (VEGFR 1–3) and tyrosine
receptor kinase 2 (TIE2). Regorafenib also has an effect in
stromal signaling, which mediates the maintenance of the
stroma or tumor microenvironment, by inhibiting platelet-
derived growth factor receptor (PDGFR) and fibroblast
growth factor receptor (FGFR). This agent also inhibits
oncogenic receptor tyrosine kinases, such as KIT and RET,
which leads to inhibition of neovascularization and cancer
cell replication [4]. Regorafenib was successfully tested in
preclinical models [4] and promising results in phase I
studies were also factors in the clinical development of this
agent [5, 6]. Further steps were the applications for the
marketing authorization of regorafenib in the treatment of
mCRC and gastrointestinal stromal tumors (GISTs) based
on data of the CORRECT [7] and the GRID trials [8],
respectively.
The recommended dose of regorafenib is 160 mg/daily
for 3 weeks, followed by 1 week with no treatment.
Although regorafenib confers survival benefits to patients
with mCRC, some adverse events (AEs) commonly asso-
ciated with the use of this agent may lead to dose reduction
or treatment interruption thus jeopardizing treatment effi-
cacy. Nonetheless, chemotherapy-associated AEs are
cumulative, whereas most AEs associated with regorafenib
may resolve within the first 8 weeks of treatment, if these
are appropriately managed [9].
This paper has been developed by ten Spanish oncolo-
gists, all of them experts in the management of patients
with mCRC and with a wide experience in the adminis-
tration of regorafenib. The aim of this review is to address
key practical aspects of regorafenib use, such as dosing,
patient monitoring, and management of the most common
drug-related AEs.
Efficacy and safety data of regorafenib in patients
with mCRC
Regorafenib was approved by the United States Food and
Drug Administration (FDA) and the European Medicines
Agency (EMA) for the treatment of adult patients with
mCRC who have previously progressed to, or are not
considered candidates for, available therapies. These
treatments include therapies based on fluoropyrimidines,
anti-VEGF and anti-epidermal growth factor receptor
(EGFR) agents in RAS wild type tumors.
CORRECT trial
CORRECT was an international, multicenter, randomized,
placebo-controlled, phase III trial including 760 patients
with previously treated mCRC, who were allocated to
receive either regorafenib (n = 505) or placebo
(n = 255), in addition to best supportive care [7]. In this
study, the recruitment was completed in 11 months.
Highlighting this latter the great need for new treatments
in this setting. The primary endpoint of the trial, overall
survival (OS), showed significant differences in favor of
the regorafenib arm [6.4 vs. 5.0 months; hazard ratio
(HR) 0.77; 95 % confidence interval (CI) 0.64–0.94;
p = 0.0052].
Secondary end points of the trial were progression-free
survival (PFS), objective response, disease control rates
and safety. Differences in terms of PFS were significantly
better with regorafenib (1.9 vs. 1.7 months, respectively;
HR 0.49; 95 % CI 0.42–0.58; p \ 0.0001). However,
partial response did not differ significantly between both
arms (1.0 vs. 0.4 %, respectively; p = 0.19). This may be
due to the fact that regorafenib is a cytostatic, rather than a
cytotoxic drug, as well as due to the fact that its activity
may not be appropriately documented by the conventional
Response Evaluation Criteria in Solid Tumors (RECIST).
Indeed, disease control rate (i.e. partial response plus stable
disease assessed at least 6 weeks after randomization) was
significantly higher in patients treated with regorafenib
(41 %) than in those allocated to the placebo arm (15 %)
(p \ 0.0001). Patients treated with regorafenib showed a
trend towards benefit in all clinical subgroups in the
CORRECT trial, including patients presenting KRAS
mutation.
The safety profile of regorafenib in the CORRECT trial
was consistent with early-phase clinical trials, as well as
with other small-molecule tyrosine kinase inhibitors
(TKIs). The most frequent severe AEs were hand-foot skin
reaction (HFSR), fatigue, diarrhea, hypertension and rash
(Table 1). Most occurred early in the course of treatment
and could be managed with dose modification or reduction.
In the CORRECT trial, patients’ quality-of-life (QoL) was
measured according to the EORTC QLQ-C30 and EQ-5D
scales. No substantial differences were found in overall
change in QoL between regorafenib-treated patients and
placebo recipients [10]. Both the EORTC QLQ-C30 and
EQ-5D scales are validated for the measurement of QoL in
patients with cancer. Although these scales do not address
some of the AEs typically associated with regorafenib, the
authors consider the overall results of this trial in terms of
QoL are relevant.
Regorafenib is the first oral multikinase inhibitor with
proven activity in patients with mCRC, achieving disease
control rate in 41 % of treated patients and a 1.4 month
absolute increase in OS, a 23 % reduction in the risk of
death, and a 51 % reduction in the risk of progression or
death. Regorafenib is generally well tolerated, with a tox-
icity profile optimally managed through early monitoring
and through optimal implementation of supportive care
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strategies. In the light of these results, it was agreed that
regorafenib should be considered a new standard of care
for patients with pretreated mCRC in all clinical and
molecular subgroups. Nevertheless, clinicians need guid-
ance for regorafenib use in patients with mCRC to optimize
drug tolerability and therefore keep a favorable benefit/risk
profile.
CONSIGN trial
The phase IIIb CONSIGN trial (ClinicalTrials.gov Iden-
tifier: NCT01538680) is a prospective, interventional,
open-label, single-arm, multicenter expanded access
study. CONSIGN aims to examine the effect of providing
regorafenib to patients with mCRC who have failed after
standard therapy and for whom no other treatment option
exists. The primary endpoint of this study is collecting
additional safety data on regorafenib in this setting.
Patients continued on treatment until reaching one of the
main study criteria, i.e. death, unacceptable toxicity,
patient’s withdrawal of consent, physician’s decision for
discontinuation or substantial noncompliance with the
protocol. If the disease is progressive, the patient may
continue treatment at the investigator’s discretion. To
date, no data have been published on the outcomes of this
trial.
Table 1 Incidence of AEs in patients with mCRC in the CORRECT trial [7]


















Fatigue 189 (38) 46 (9) 2 (\1) 237 (47) 58 (23) 12 (5) 1 (\1) 71 (28)
HFSR 150 (30) 83 (17) 0 (0) 233 (47) 18 (7) 1 (\1) 0 (0) 19 (8)
Diarrhea 133 (27) 35 (7) 1 (\1) 169 (34) 19 (8) 2 (1) 0 (0) 21 (8)
Anorexia 136 (27) 16 (3) 0 (0) 152 (30) 32 (13) 7 (3) 0 (0) 39 (15)
Voice changes 146 (29) 1 (\1) 0 (0) 147 (29) 14 (6) 0 (0) 0 (0) 14 (6)
Hypertension 103 (20) 36 (7) 0 (0) 139 (28) 13 (5) 2 (1) 0 (0) 15 (6)
Oral mucositis 121 (24) 15 (3) 0 (0) 136 (27) 9 (4) 0 (0) 0 (0) 9 (4)
Rash 101 (20) 29 (6) 0 (0) 130 (26) 10 (4) 0 (0) 0 (0) 10 (4)
Nausea 70 (14) 2 (\1) 0 (0) 72 (14) 28 (11) 0 (0) 0 (0) 28 (11)
Weight loss 69 (14) 0 (0) 0 (0) 69 (14) 6 (2) 0 (0) 0 (0) 6 (2)
Fever 48 (10) 4 (1) 0 (0) 52 (10) 7 (3) 0 (0) 0 (0) 7 (3)
Constipation 42 (8) 0 (0) 0 (0) 42 (8) 12 (5) 0 (0) 0 (0) 12 (5)
Dry skin 39 (8) 0 (0) 0 (0) 39 (8) 7 (3) 0 (0) 0 (0) 7 (3)
Alopecia 36 (7) 0 (0) 0 (0) 36 (7) 1 (\1) 0 (0) 0 (0) 1 (\1)
Taste alteration 35 (7) 0 (0) 0 (0) 35 (7) 5 (2) 0 (0) 0 (0) 5 (2)
Vomiting 35 (7) 3 (1) 0 (0) 38 (8) 13 (5) 0 (0) 0 (0) 13 (5)
Sensory neuropathy 32 (6) 2 (\1) 0 (0) 34 (7) 9 (4) 0 (0) 0 (0) 9 (4)
Nose bleed 36 (7) 0 (0) 0 (0) 36 (7) 5 (2) 0 (0) 0 (0) 5 (2)
Dyspnea 27 (5) 1 (\1) 0 (0) 28 (6) 4 (2) 0 (0) 0 (0) 4 (2)
Muscle pain 26 (5) 2 (\1) 0 (0) 28 (6) 6 (2) 1 (\1) 0 (0) 7 (3)
Headache 23 (5) 3 (1) 0 (0) 26 (5) 8 (3) 0 (0) 0 (0) 8 (3)
Pain in the abdomen 24 (5) 1 (\1) 0 (0) 25 (5) 10 (4) 0 (0) 0 (0) 10 (4)
Laboratory abnormalities
Thrombocytopenia 49 (10) 13 (3) 1 (\1) 63 (13) 4 (2) 1 (\1) 0 (0) 5 (2)
Hyperbilirubinemia 35 (7) 10 (2) 0 (0) 45 (9) 2 (1) 2 (1) 0 (0) 4 (2)
Proteinuria 28 (6) 7 (1) 0 (0) 35 (7) 3 (1) 1 (\1) 0 (0) 4 (2)
Anemia 19 (4) 12 (2) 2 (\1) 33 (7) 6 (2) 0 (0) 0 (0) 6 (2)
Hypophosphatemia 6 (1) 19 (4) 0 (0) 25 (5) 0 (0) 1 (\1) 0 (0) 1 (\1)
Treatment-related AEs occurring in C5 % of patients
AEs adverse events, BSC best supportive care, HFSR hand-foot skin reaction, mCRC metastatic colorectal cancer
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Incidence and management of the most common side
effects of regorafenib
Fatigue/asthenia
Fatigue is a subjective symptom of exhaustion which
increases gradually. Unlike weakness, fatigue can improve
after a period of resting. In a phase I study conducted by
Strumberg et al. [6] on 38 patients with heavily pretreated
mCRC, 50 % of patients presented fatigue of any grade and
11 % of them showed grade C3 fatigue during their
treatment with regorafenib. This symptom was one of the
most common treatment-related AEs in this trial. Overall,
regorafenib was permanently discontinued due to AEs in
11 (29 %) patients and in 1 of the patients treated at the
160 mg dose level, treatment discontinuation was due to
fatigue. In the phase III CORRECT trial [7], fatigue was
also among the most common regorafenib-related AEs,
both at any grade (47 vs. 28 %), and at grade C3 (10 vs.
5 %) compared to placebo.
According to an analysis conducted by Grothey et al.
[11] regarding the time course of regorafenib-related AEs,
common grade 3 AEs occur early during the course of
treatment and stabilize over time. The incidence of grade 1
and 3 fatigue was 19, 18 and 7 %, respectively, during the
first cycle of treatment. The incidence of fatigue appeared
to stabilize between the seventh and eighth cycles, occur-
ring in 10 % of patients at this time point. In this analysis,
the incidence of other common grade 3 AEs was also
demonstrated to decrease over time.
As fatigue is a common symptom of cancer patients and
its origin is often multifactorial (advanced cancer, drug
toxicity, anemia, comorbidities, etc.), sometimes clinicians
find difficulties in assessing to what extent the antineo-
plastic agent is contributing to it. Fatigue grade C2 has an
impact in patients’ QoL, and it is important to highlight
that patients should be made aware that fatigue may be
affecting them prior to treatment initiation with regorafe-
nib. As an AE of regorafenib, however, early action against
fatigue plays a key role in patients treated with regorafenib.
Therefore, during the first two cycles of treatment, moni-
toring for fatigue should be conducted every week, either
by an oncologist or by a nurse. After the first two cycles,
monitoring may be done less frequently.
Clinicians have to bear in mind that after the first
medical appointment, the effect of regorafenib on fatigue
can be controlled in several ways, such as reducing the
dose of regorafenib (Fig. 1), treatment interruption and/or
the administration of concomitant medications to the
patient. Special attention should be also paid to other
potentially treatable co-existing causes of fatigue such as
anemia, and appropriate treatment initiated if indicated.
During the second cycle of treatment and thereafter, an
improvement in the control of fatigue is frequently
achieved and, thus, less frequent monitoring is required.
Asthenia–anorexia syndrome can be treated with cortico-
steroid medication [12], or with the administration of
medroxyprogesterone [13]. However, the convenience of
these treatments for patients with mCRC is an aspect under
discussion. Overall, initial management of fatigue includes
treating common causes of fatigue, such as pain, sleep
disturbance and anemia. These conditions can improve
with medical treatment. Proper nutrition and prevention of
malnutrition, anorexia and dehydration may also help
reduce fatigue. Regular exercise is also recommended to
patients with a good physical status [14]. In addition,
patients with any grade of fatigue should be checked thy-
roid-stimulating hormone (TSH) levels [15]. In the other
hand, when severe fatigue occurs, regorafenib treatment
should be interrupted until the patient’s energy levels have
recovered.
Hand-foot skin reaction
Palmar-plantar erythrodysesthesia syndrome or HFSR is a
disorder characterized by redness, marked discomfort, and
swelling and tingling in palms or soles. This syndrome is
characterized by localized thick hyperkeratotic lesions that
may be surrounded by erythematous regions within the skin,
which are often painful. According to the phase III COR-
RECT trial [7], HFSR of any grade is very common (47 %)
and grade 3 HFSR is common (17 %) in patients with mCRC
treated with regorafenib. These lesions usually occur within
the first 2–4 weeks of regorafenib administration and can
negatively impact physical, psychological and social well-
being of patients, thereby affecting their QoL. HFSR is the
most common toxicity leading to dose reductions or treat-
ment interruptions in patients receiving regorafenib and
these side effects start early in patients’ treatment.
In patients treated with regorafenib, HFSR should be
monitored weekly during the first two cycles and every
4 weeks thereafter. Early detection of HFSR is a key to
prevent worsening of this condition (Fig. 2). Main pro-
phylactic measures include skin examination before treat-
ment initiation, softening and removal of calluses,
protection against pressure and friction (i.e. plantar pads,
adequate footwear, etc.) and the frequent use of creams and
moisturizers from the start of therapy. To soften the skin of
the hands and feet non-urea-based creams should be
applied, whereas keratolytic creams, containing urea or
salicylic acid 6 % can be used on hyperkeratotic areas. To
exfoliate callused skin, patients can use alpha hydroxyl
acid-based creams (5–8 %) 2 times a day [16] (Fig. 3).
In cases of HFSR grade C2, a dermatologist consulta-
tion is recommended, and also the use of non-steroidal
anti-inflammatory drugs (NSAIDS). The key objectives of
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HFSR management strategies for healthcare providers are
to maintain or restore patient comfort and QoL, to avoid
interference with patient’s daily activities and also to
maintain their treatment with regorafenib for as long as
possible. Accurate grading of HFSR is critical to select the
appropriate management strategies. Dose reduction or
treatment interruption may be required in some instances,
which usually leads to the alleviation of symptoms in
1–2 weeks. Patients should be made aware of the impor-
tance of informing their healthcare team as soon as the first
symptoms of HFSR are noticed. Patients must also be
aware of the best practices for managing HFSR, as well as
the steps that can be taken to lessen the severity of this
reaction before and during their treatment with regorafenib.
Diarrhea
Diarrhea is defined as having three or more loose or liquid
stools per day, or an increase in the defecatory frequency
over baseline for that particular patient. Diarrhea can be
accompanied by pain, defecating emergency or inconti-
nence, and, in severe cases, may cause fluid and electrolyte
depletion leading to dehydration, renal failure and even
cardiovascular compromise. Therefore, adequate early
intervention is key to prevent severe complications. When
a patient reports diarrhea, some questions shall be formu-
lated in order to better adjust treatment, such as the pre-
sence of fever, number of stools/day, consistency and
color, symptom duration, presence of nausea and vomiting,
abdominal pain, concomitant medication and type of
abdominal surgery performed (whether the patient under-
went a colostomy or an ileostomy). In the phase III
CORRECT trial [7], diarrhea was reported in 34 % of
patients with mCRC treated with regorafenib and in 7 % of
them it was grade 3–4. Grade 3–4 diarrhea is the third most
common side effect reported in the CORRECT trial, and
the incidence of grade 3 diarrhea is constant throughout the
treatment.
Fig. 1 Dose modification/delay for toxicities related to regorafenib
(except hand-foot skin reaction, hypertension and liver function test
abnormalities). According to Common Terminology Criteria for
Adverse Events (CTCAE) v 4.0. aExcludes alopecia, non-refractory
nausea/vomiting, non-refractory hypersensitivity and asymptomatic
laboratory abnormalities. bIf no recovery after a 4 week delay,
treatment will be permanently discontinued
946 Clin Transl Oncol (2014) 16:942–953
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The incidence of grade 3–4 regorafenib-induced diar-
rhea seems to be higher than that observed in patients
treated with drugs such as cetuximab in monotherapy
(1.7 %) [17], and higher than that reported with other
commonly used antineoplastic regimens in mCRC, such as
FOLFIRI (10.5 %), FOLFIRI plus cetuximab (15.7 %),
FOLFOX4 (9 %), FOLFOX4 plus panitumumab (18 %)
and cetuximab plus irinotecan (21 %) [17–19]. Treatment
of diarrhea is an important aspect in patients receiving this
drug. The treatment may include anti-diarrhea diet (avoid
fiber and fat), intensive oral rehydration with liquids that
contain water and electrolytes, and the use of anti-diarrheal
drugs such as loperamide and/or codeine every 4–8 h.
Regorafenib may also be suspended to allow the patient’s
recovery (i.e. when diarrhea reaches grade [2), and then
treatment restarted at a lower dose (Fig. 1).
Anorexia/weight loss
Anorexia is also a frequent symptom in mCRC patients
treated with regorafenib. Thirty percent of patients treated
with regorafenib presented this AE in comparison with
15 % of patients in the placebo arm in the CORRECT trial
[7]. However, there was no difference in the percentage of
patients treated with regorafenib or placebo (3 %) who had
grade 3 anorexia. With regard to weight loss, 14 vs. 2 % of
patients with mCRC evaluated in this trial showed weight
loss, respectively. Anorexia is a disorder frequently asso-
ciated with other AEs in cancer patients. Weight loss can
be easily measured; in contrast, anorexia is more sub-
jective. Although both AEs are frequently related, patients
can also present weight loss due to diarrhea, regardless of
the presence of anorexia. Demetri et al. [8] conducted the
GRID phase III trial that included 199 patients diagnosed
with metastatic or unresectable GISTs. These patients had
failed to respond to at least one previous administration of
imatinib and sunitinib. In this trial, a lower percentage of
patients in both study arms (21 % regorafenib arm vs. 8 %
placebo arm) showed anorexia in comparison with the
CORRECT trial.
Healthcare staff should ask patients at every medical
appointment about their appetite and patients’ weight
Fig. 2 Dose modification/delay of regorafenib in patients with hand-
foot skin reaction. According to Common Terminology Criteria for
Adverse Events (CTCAE) v 4.0. aIn case of grade 3 hand-foot skin
reaction, a dose re-escalation is permitted only during first occur-
rence. ADL activities of daily living, HFSR hand-foot skin reaction
Clin Transl Oncol (2014) 16:942–953 947
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should be monitored in every cycle of treatment. The
prophylaxis and management of the AE weight loss
includes a hypercaloric diet, dietary supplements and the
administration of megestrol acetate, as well as consulting
an endocrinologist in some circumstances. However, as
in patients presenting with fatigue, the convenience of
the administration of corticoids to patients with anorexia
is an aspect that is under discussion. It is important to
highlight that anorexia and weight loss are frequent or
very frequent AEs in patients treated with TKIs [20].
There are no data regarding the first occurrence of this
AE and its outcome in patients treated with regorafenib,
and there are no special requirements regarding anorexia
in patients treated with this agent in this setting. In
addition, clinicians have to bear in mind that patients
with cancer can quickly lose 3–4 kg (grade 1 weight
loss) but such weight loss does not require dose reduc-
tion. Nevertheless, grade 3 anorexia does require a dose
reduction (Fig. 1).
Hypertension
Hypertension is common in patients treated with rego-
rafenib; however, the effect of this agent on hypertension is
not cumulative. The overall incidence of hypertension in
the CORRECT trial was 28 and 6 % in patients treated in
the regorafenib and placebo arms, respectively. The inci-
dence of grade 3 hypertension was 7 and 1 %, respectively
[7]. Nonetheless, the incidence of hypertension was higher
in the GRID trial [8], as 58.5 % of patients treated with
regorafenib presented this AE and in 23 % of them it was
of grade 3. Several clinical trials carried out in patients
treated with other TKIs have demonstrated similar or
higher rates of hypertension in patients with mCRC or with
GISTs treated with drugs such as sorafenib (all grades
23 %; grade 3–4 6 %), sunitinib (all grades 22 %; grade
3–4 7 %), pazopanib (all grades 36 %; grade 3–4 4 %),
axitinib (all grades 40 %; grade 3–4 13 %), and regorafe-
nib (all grades 36 %, grade 3–4 11 %) [7, 8, 21–23].
Fig. 3 Management of treatment-emergent hypertension in patients treated with regorafenib. According to Common Terminology Criteria for
Adverse Events (CTCAE) v 4.0. DBP diastolic blood pressure, HBP high blood pressure, SBP systolic blood pressure, WNL within normal limits
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It is important to bear in mind that hypertension occurs
more frequently during the first two cycles of treatment
with regorafenib, but this AE is controlled in subsequent
treatment cycles [11]. Measurement of blood pressure is
recommended before treatment initiation and then, careful
consideration shall be given to initiate or adjust antihy-
pertensive medication if required (Fig. 3). Following
treatment initiation, monitoring of blood pressure twice a
week is advised during the first 2 weeks of therapy and
once per week thereafter. If blood pressure is stable, the
monitoring frequency may be subsequently reduced.
Hypertensive patients are recommended to have their blood
pressure monitored more frequently. Overall, hypertension
usually occurs with mild or moderate severity in patients
treated with regorafenib and after 2 weeks of treatment
with this drug. Nevertheless, this AE is generally asymp-
tomatic and rarely impairs patient’s QoL. In addition,
hypertension is easily manageable with appropriate medi-
cation and, when required, regorafenib treatment can be
temporarily interrupted and/or dose can be reduced.
Mucositis
Mucositis is the type of toxicity related to cancer treatment
most commonly affecting QoL. The high epithelial
replacement rate in mucosal tissue makes it vulnerable to
damage by antineoplastic agents. Signs of this condition
include atrophy of the epithelial tissue accompanied by
erythema and edema, sensation of dryness and burning in
the mouth, odynophagia and cotton mouth. Grade C2
mucositis is also accompanied by pain and interferes with
oral intake, potentially leading to dehydration and weight
loss. Several guidelines address the prophylaxis and man-
agement of mucositis, and some key aspects described in
these guidelines are mentioned below [24–30].
Mucositis associated with biologic therapy is due to
several mechanisms that differ from the mechanisms rela-
ted to chemotherapy and which are not well-known. This
AE affects 40 % of patients treated with standard chemo-
therapy, 80 % of patients treated with high-dose chemo-
therapy and 100 % of patients treated with radiotherapy to
the head and neck. In patients treated with biologic thera-
pies, the incidence of mucositis varies from 10 to 40 %,
reaching 72 % in patients treated with afatinib. The
mechanism of development of mucositis in patients treated
with TKIs is not clear either; however, it seems to be
related to impaired healing of microtraumas in these
patients. Symptoms such as dysgeusia, dysphagia and
aphthous ulcer are more frequently observed in patients
treated with TKIs than in patients developing mucositis
induced by conventional cytotoxic agents. The adminis-
tration of a TKI together with a FOLFIRI regimen can
increase the incidence and grade of mucositis. The
incidence of mucositis in patients treated with TKIs fluc-
tuates from 4 % (in patients treated with pazopanib) to
51 % (in patients treated with cabozantinib). The incidence
of mucositis in the CORRECT trial was 27 and 4 % in
patients in the regorafenib and placebo arms [7], respec-
tively (3 and 0 %, respectively, showed grade 3). The
mechanism for the development of mucositis in patients
treated with regorafenib is still unknown, including the
time point at which initiation of mucositis occurs in
patients treated with this agent, whether this reaction is
related to other toxicities and whether its recovery is sim-
ilar to chemotherapy-related mucositis.
The risk factors involved in the development of this AE
include age (the younger the patient, the greater the toxicity
in the mucosal tissue), poor oral hygiene, nutritional status,
tumor location (worse in tumors of head and neck) and type
of treatment administered to the patient. Clinicians have to
bear in mind these risk factors in order to prevent the
occurrence of mucositis. In addition, the development of
this AE can be accompanied by complications such as local
and systemic infections, especially in patients presenting
neutropenia \1,000 U/lL. Prophylaxis of mucositis
includes appropriate oral hygiene, consultation with an
odontologist (particularly important before treatment ini-
tiation) and the avoidance of spicy, acid, hard or hot food
and drinks. With regard to treatment, recommendations
include a high-protein diet and adequate hydration. In cases
of severe mucositis, enteral or parenteral nutrition is
advisable. Mucositis can also be treated with the use of
gentle mouthwashes after meals and topical anesthetics.
There are also products that cover the mucosal tissue, some
of them present hyaluronic acid in their composition. This
type of oral gels creates a film over the mucosa and protects
it from the effects of food, liquids and saliva. Analgesics
are also effective against mucositis. These agents include
topical mouthwashes, opioid analgesics and anti-inflam-
matory drugs. Lastly, dose modifications and treatment
interruptions can also alleviate the symptoms of this AE
and are recommended in patients developing grade C3
mucositis and may be considered in case of prolonged
grade 2 (Fig. 1).
Skin rash
Skin rash is characterized by the presence of macules, i.e.
flat, discolored areas of skin, and papules, or solid eleva-
tions of skin. Rash symptoms include photosensitivity,
erythema, dry or peeling skin, blistering and pruritus [31].
Patients must be made aware of skin toxicities, especially
HFSR and rash, when they are treated with antineoplastic
drugs such as regorafenib [32]. Another key aspect is that
skin toxicities need to be appropriately graded. Rash is
common in patients treated with regorafenib, particularly
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of mild and moderate severity. In the phase I study carried
out by Mross et al. in patients with advanced solid tumors
treated with regorafenib, rash occurred in patients who
were on a dose of 120 mg/day or higher. In the CORRECT
trial, 26 % of patients presented rash in the regorafenib arm
and 6 % of them had grade 3 rash. Like other AEs com-
monly associated with regorafenib, rash occurs early,
during the first and second cycle of treatment, and its
incidence stabilizes over time [11]. Interestingly, this AE is
more frequent in women 40–60 years old. Thus, prophy-
lactic measures should be especially addressed for this
subpopulation of patients with mCRC. Rash associated
with regorafenib is defined by areas of inflamed blotching
alternating with pale areas in the skin. This AE can be
accompanied by fever and detriment of the general con-
dition in patients treated with this drug.
Rash should be monitored every week during the first
two cycles of treatment with regorafenib, and every
4 weeks thereafter. From the beginning of treatment, pro-
phylaxis plays a key role. Some prophylactic measures
include the regular use of emollients (those not containing
alcohol), use of mild soaps and avoiding extreme temper-
atures and direct sun exposure. The treatment of rash
includes antihistamine medication and short-time use of
topical corticoids. Dermatologist consultation is advised to
adopt the most appropriate treatment for every patient.
Dose modification or treatment interruption of regorafenib
may be also required in some patients, depending on the
severity of this AE (Fig. 1).
Metabolic abnormalities
Hypothyroidism
Although no information is available regarding drug-
induced hypothyroidism in the publication of the COR-
RECT trial [7], this information was recorded in this study
and it is available in the Summary of Product Character-
istics of EMA [33]. Overall, tests on TSH showed post
baseline increase over upper limit of normal (ULN) in
23 % of patients in the regorafenib arm and in 13 % of
patients in the placebo arm. TSH post baseline [4 times
ULN was reported in 4 % of patients treated with rego-
rafenib and in no patients treated with placebo. Concen-
tration of free triiodothyronine (FT3) post baseline below
lower limit of normal (LLN) was reported in 21 and 16 %
of patients in the regorafenib and placebo arms, respec-
tively. Concentration of free thyroxin (FT4) post baseline
\LLN was reported in 8 % of patients treated with rego-
rafenib and in 7 % of patients treated with placebo. In
another trial, Demetri et al. [8] reported 18 % of hypo-
thyroidism in patients with GISTs treated with regorafenib
in the GRID trial. None of these patients presented grade
C3 hypothyroidism. Grade C2 hypothyroidism requires
treatment and, in some cases, the advice of an endocri-
nologist. This is a common class effect of TKIs but is
generally mild, rarely symptomatic and easily manageable
with hormone replacement therapy when appropriate.
Hypophosphatemia
Other metabolic abnormalities detected in the CORRECT
trial include hypophosphatemia [7], which occurred in 5 %
of patients and in 4 % of them this AE was grade 3.
Hypophosphatemia symptoms include weakness, tiredness,
musculoskeletal pain, and it can be caused by diarrhea or
elimination by the kidney, so diagnosis requires the
determination of levels of phosphate in the urine. When
this AE persists, oral phosphate can be administered either
through diet or dietary supplements. Moderate hypophos-
phatemia does not require any other treatment. However,
severe hypophosphatemia requires administration of iv
phosphate.
Hepatic and pancreatic enzymes
With regard to the hepatic enzymes alanine aminotrans-
ferase (ALT) and aspartate aminotransferase (AST), both
presented grade C3 increase in about 6 % of patients
treated with regorafenib in the CORRECT trial [34],
whereas bilirubin levels reached grade C3 increase in about
12 % of patients. Elevation of hepatic enzymes and bili-
rubin levels can be reduced by adjusting regorafenib dose.
Their level should be monitored 1 week before treatment
initiation, at least every 2 weeks during the first 2 months
of treatment and monthly thereafter unless otherwise clin-
ically indicated. As a general rule, regorafenib treatment
should be withdrawn if the patient does not recover to
baseline values after 4 weeks of treatment interruption or
after 2 levels of dose reduction (Fig. 4). Patients with
active viral hepatitis should be evaluated with caution,
analyzing their hepatic function and maximizing monitor-
ing, due to the fact that these patients have been excluded
of the CORRECT and CONSIGN trials. Nonetheless, so-
rafenib is a drug with similar characteristics to regorafenib
and is administered to patients presenting hepatomas and
the majority of these patients have active hepatitis B or C.
In the CORRECT trial, lipase elevations occurred in 6
and 1 % of patients allocated in the regorafenib and pla-
cebo arms, respectively, whereas severe lipase elevations
occurred in 4 and 1 % of patients, respectively [34]. In
patients presenting abdominal pain, lipase and amylase
values should be analyzed. Nonetheless, patients presenting
lipase and amylase elevations can be asymptomatic.
Clinicians should also warn patients about these poten-
tial side effects of regorafenib use. Nonetheless, the
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majority of metabolic abnormalities occur during the first
two cycles of treatment.
Lastly, hematological abnormalities and especially
severe hematological abnormalities, are neither frequent
nor very relevant in patients treated with regorafenib. In
case of occurrence, clinicians should bear in mind the
recommendations of the guidelines on hematological tox-
icity as a side effect of chemotherapy.
Conclusions and recommendations for general practice
Regorafenib 160 mg/day orally, administered for 21 days
every 4 weeks, is an active treatment, which increases
survival in patients with mCRC who have failed to other
standard therapies.
The selection of patients undergoing treatment with
regorafenib plays a key role in this setting. Eligible patients
need to fulfill four criteria: (i) ECOG = 0–1, (ii) absence
of poorly-controlled hypertension, i.e. basal hypertension
C150/90 mmHg; thus, in patients presenting with abnor-
mal blood pressure, hypertension has to be corrected with
the administration of antihypertensive therapy before
treatment initiation with regorafenib, (iii) absence of severe
cardiovascular disease during the last 6 months, and (iv)
adequate bone marrow, liver and renal functions. Besides
these four criteria, clinicians have to pay particular atten-
tion to the occurrence of warning signs such as hyperten-
sion, asthenia, HFSR, rash, mucositis or an abnormal
increase in the level of hepatic enzymes during the first
days or weeks of treatment with regorafenib. These signs
could worsen during subsequent days or weeks if
Fig. 4 Dose modification/delay for ALT and/or AST and/or bilirubin
increases related to regorafenib. According to Common Terminology
Criteria for Adverse Events (CTCAE) v 4.0. aIf all values remain
stable for two cycles, dose re-escalation may be considered at the
discretion of the investigator. After re-escalation ALT, AST and
bilirubin should be checked twice a week for 2 weeks, followed by
weekly assessments for at least 4 weeks. bIn case of discontinuation
ALT, AST and bilirubin should be checked twice a week for 2 weeks,
followed by weekly assessments until recovery to baseline. General
notes: patients requiring interruption for 4 weeks must stop treatment
permanently. If more than 2 dose reductions are required, treatment
will be discontinued. ALT alanine aminotransferase, AST aspartate
aminotransferase, ULN upper limit of normal
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oncologists do not carry out the appropriate treatment
interruptions or dose adjustments.
Regorafenib should be taken in the morning, accompa-
nied by a low-fat breakfast. It is important to highlight that
the most frequent and relevant toxicities associated with
regorafenib occur during the first weeks of treatment. For
this reason, patients receiving this agent should be moni-
tored weekly during the first two cycles of treatment and
monthly thereafter. The incidence of grade 3–4 AEs can be
reduced with the implementation of appropriate prophy-
lactic measures and also paying special attention to the
appearance of grade 2 AEs, in order to prevent them from
worsening. In this regard, clinicians should confirm that the
toxicities detected during the administration of prior cycles
of regorafenib present at grade B1 before the patient
receives a new cycle of regorafenib therapy. Also, to lessen
the grade of toxicity associated with regorafenib, the dose
of this agent can be reduced by one dose level to 120 mg/
day. This dose can be further reduced, when required, by a
second dose level to 80 mg/day. However, in this regard,
there is no evidence of the occurrence of accumulated
toxicity in patients receiving regorafenib.
Patients must also be made aware of the toxicity profile
of regorafenib, as well as about the prophylactic measures
at their disposal. For example, some prophylactic measures
to prevent skin toxicities include the use of mild soaps,
intense hydration, comfortable clothes and shoes in order to
prevent chafing in the skin and avoiding clothes that do not
allow adequate ventilation of perspiration. In addition,
patients using regorafenib must maintain appropriate oral
hygiene to prevent, or avoid the worsening of, mucositis.
Lastly, metabolic abnormalities, such as hypophosphatemia
and hypothyroidism, should be monitored at least once a
month and the dose of regorafenib should be modified
when required. Overall, while being aware of the safety
profile of regorafenib and how to manage the most com-
mon toxicities related to it, this agent should be regarded as
a new standard of care in late-stage mCRC.
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